ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of April 17, 2026, ALGS stock price declined to $6.68 with 738,475 million shares trading.

ALGS has a beta of 0.99, meaning it tends to be less sensitive to market movements. ALGS has a correlation of 0.02 to the broad based SPY ETF.

ALGS has a market cap of $41.33 million. This is considered a Sub-Micro Cap stock.

Last quarter Aligos Therapeutics reported $169,000 in Revenue and -$1.91 earnings per share. This fell short of revenue expectation by $-97,670 and exceeded earnings estimates by $.42.

In the last 3 years, ALGS traded as high as $46.80 and as low as $3.76.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, AVSC, DCOR.

ALGS has outperformed the market in the last year with a return of +42.7%, while the SPY ETF gained +36.3%. However, in the most recent history, ALGS shares have underperformed the stock market with its stock returning -15.9% in the last 3 month period and -16.2% for the last 2 week period, while SPY has returned +2.9% and +8.3%, respectively.

ALGS support price is $7.11 and resistance is $8.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.